Category: C.R. BardSyndicate content

ConvaTec said to explore 2015 sale

August 19, 2014 by Brad Perriello

ConvaTec is reportedly weighing a sale of the private-equity-owned medical device company next year, even as interest in a Medtronic-like inversion deal mounts from C.R. Bard, CareFusion and 3M.

ConvaTec said to explore 2015 sale

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

BSX wins personal injury lawsuit over its Pinnacle pelvic mesh product | Medtech legal news for the week of August 4, 2014

August 4, 2014 by MassDevice

Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific prevails in 1st pelvic mesh trial; Bard settles more than 500 pelvic mesh complaints; Edwards: Q2 brings double-digit sales bump, a major Medtronic settlement and a rosier outlook on the year; Ex-sales rep's counter-claims stand in poaching spat with Stryker; ResMed kicks Apex sleep masks out of Germany

Boston Scientific prevails in 1st pelvic mesh trial

July 30, 2014 by Brad Perriello

Smith & Nephew plans to reveal new strategy for mature markets | Medtech Wall Street news for the week of July 28, 2014

July 31, 2014 by MassDevice

Here's a look at some of the top Wall Street stories for medical device companies this week: Smith & Nephew CEO reveals new 'no frills' strategy; Bard: We're on track for early 2015 Lutonix approval; Ocular Therapeutix prices IPO below range; Philips' healthcare business suffers in Q2; Intersect ENT prices IPO at low end of range

Smith & Nephew CEO reveals new 'no frills' strategy

July 28, 2014 by Brad Perriello

Boston Scientific, other medtech giants weigh in on mega-mergers

July 29, 2014 by Arezu Sarvestani

A recent spate of mega-mergers hasn't inspired medtech peers to follow suit just yet, according to leadership at Boston Scientific, C.R. Bard and Smith & Nephew.

Boston Scientific, other medtech giants weigh in on mega-mergers

The medical device industry has some blockbuster merger activity in recent months, but a few companies are sitting this one out.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Bard settles more than 500 pelvic mesh complaints

July 29, 2014 by Arezu Sarvestani

C.R. Bard closes the books on more than 500 patient injury complaints associated with its Avaulta pelvic mesh implants for an undisclosed amount.

Bard settlement closes more than 500 pelvic mesh complaints

C.R. Bard (NYSE:BCR) managed to close the books on a large chunk of patient complaints against its Avaulta mesh implant, settling more than 500 cases in its 2nd quarter.

Bard: We're on track for early 2015 Lutonix approval

July 25, 2014 by Brad Perriello

Executives at C.R. Bard say the company is on track for an early 2015 approval for its Lutonix drug-eluting balloon for treating peripheral artery disease.

Bard: We're on track for early 2015 Lutonix approval

C.R. Bard (NYSE:BCR) is on track for an early 2015 U.S. approval of its Lutonix drug-eluting balloon, company executives said yesterday after reporting earnings growth that topped expectations.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Covidien logs $180M charge over pelvic mesh lawsuits

July 11, 2014 by Brad Perriello

Covidien says its exposure to a raft of product liability lawsuits filed over pelvic mesh products increased by some $131 million during its fiscal 3rd quarter.

Covidien logs $180M charge over pelvic mesh lawsuits

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp